Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-10), CSPC Pharmaceutical Group's 3-1 Month Momentum % is -1.89%.
The industry rank for CSPC Pharmaceutical Group's 3-1 Month Momentum % or its related term are showing as below:
CSPCY's 3-1 Month Momentum % is ranked better than 57.7% of 1019
companies
in the Drug Manufacturers industry
Industry Median: -7.87
vs CSPCY: -1.89
CSPC Pharmaceutical Group (OTCPK:CSPCY) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
CSPC Pharmaceutical Group 3-1 Month Momentum % Related Terms
CSPCY vs LLY, JNJ, ABBV: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSPC Pharmaceutical Group 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where CSPC Pharmaceutical Group's 3-1 Month Momentum % falls into.
CSPC Pharmaceutical Group (OTCPK:CSPCY) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSPC Pharmaceutical Group (CSPCY) has a 3-1 Month Momentum % of -1.89% as of Aug. 10, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on CSPC Pharmaceutical Group and its competitors. According to the industry distribution chart, CSPC Pharmaceutical Group ranks #431 out of 1019 companies in the Drug Manufacturers industry, placing it in the top 42.3%.
Is CSPC Pharmaceutical Group's 3-1 Month Momentum % too high?
CSPC Pharmaceutical Group's current 3-1 Month Momentum % is -1.89%. Based on the distribution chart, CSPC Pharmaceutical Group ranks #431 out of 1019 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, CSPC Pharmaceutical Group has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CSPC Pharmaceutical Group's 3-1 Month Momentum % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, CSPC Pharmaceutical Group ranks #431 out of 1019 companies for 3-1 Month Momentum %. This puts CSPC Pharmaceutical Group in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on CSPC Pharmaceutical Group and its competitors. CSPC Pharmaceutical Group's current 3-1 Month Momentum % is -1.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSPC Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group (CSPCY) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.58, compared to a current price of $4.40 — trading 22.9% above its estimated fair value. The current 3-1 Month Momentum % is -1.89%. CSPC Pharmaceutical Group's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For CSPC Pharmaceutical Group (CSPCY), the current 3-1 Month Momentum % is -1.89% as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSPC Pharmaceutical Group (CSPCY) Overvalued in 2026?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group stock appears to be overvalued.
The current stock price of $4.40 is trading 22.9% above its estimated GF Value™ of $3.58.
GuruFocus considers CSPC Pharmaceutical Group to be Modestly Overvalued.
Key valuation signals for CSPCY:
3-1 Month Momentum %: -1.89%
GF Value™: $3.58 vs. price of $4.40 (22.9% above fair value)
No single metric tells the full story. See the CSPCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
79GF Score
Get the complete analysis for CSPCY
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSPCY has been successfully added to your 
